Novel agents in the treatment of multiple myeloma: a review about the future-Reference-Cited by-同舟云学术

Novel agents in the treatment of multiple myeloma: a review about the future

Published:2016-06-30 Issue:1 Volume:9 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Naymagon Leonard,Abdul-Hay Maher^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-016-0282-1

Reference117 articles.

1. Surveillance, Epidemiology, and End Results Program Turning Cancer Data Into Discovery. 2015 [cited 2015 October 22]; Myeloma. Surveillance, Epidemiology, and End Results Program. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html . Accessed 22 Oct 2015.

2. Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125(20):3049–58.

3. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125(20):3069–75.

4. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60.

5. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012;122(10):3456–63.

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KIAA1429 increases FOXM1 expression through YTHDF1–mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma;Cell Biology and Toxicology;2024-07-26

2. Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions;Pharmaceuticals;2024-06-25

3. Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance;European Journal of Medicinal Chemistry;2024-05

4. A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab;Expert Opinion on Drug Safety;2024-04-10

5. Exploring cellular immunotherapy platforms in multiple myeloma;Heliyon;2024-03